Genmab AS - Company Profile
Powered by 
All the data and insights you need on Genmab AS in one report.
$295
- Save hours of research time and resources with
our up-to-date Genmab AS Strategy Report
- Understand Genmab AS position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Genmab AS (Genmab) is a biotechnology company that develops differentiated human antibody therapies for the treatment of cancer and other diseases. The company's marketed antibodies include ofatumumab (Kesimpta) for the treatment of relapsing multiple sclerosis, daratumumab (Darzalex) for the treatment of AL amyloidosis and multiple myeloma, and teprotumumab (Tepezza) for thyroid eye disease. Its products are based on proprietary antibody technologies, namely, HexaBody, DuoBody, DuoHexaBody, and HexElect technologies. The company works in partnership with various pharmaceutical and biotechnology companies for the co-development and commercialization of antibody-based products. It operates in Denmark, the Netherlands, Japan and the US. Genmab is headquartered in Copenhagen, Denmark.
Headquarters
Denmark
Address
Kalvebod Brygge 43, Koebenhavn V, 1560
Website
www.genmab.com
Telephone
45 70202728
No of Employees
2,204
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
GMAB (CPH)
Revenue (2022)
$2.4B
13.6%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-20.2%
(2022 vs 2021)
Market Cap*
$19.5B
Net Profit Margin (2022)
XYZ
-29.7%
(2022 vs 2021)
* As of and is in US$
Genmab AS premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Kesimpta (Ofatumumab) – Relapsing Multiple Sclerosis | Darzalex |
| Darzalex (Daratumumab) – Multiple Myeloma | Tepezza |
| Tepezza (Teprotumumab) – Thyroid Eye Disease | Kesimpta |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Plans/Strategy | In April, the company announced its plans to acquire ProfoundBio for US$1.8 billion. |
| 2023 | Contracts/Agreements | In September, the company and Owkin entered into a research agreement for a deeper understanding of the complex biological profiles of cancer patients. |
| 2023 | Regulatory Approval | In September, the company secured conditional marketing authorization from the European Commission for TEPKINLY as a monotherapy to treat adults with relapsed or refractory diffuse large B-cell lymphoma. |
Competitor Comparison
| Key Parameters | Genmab AS | Bayer AG | Sanofi | Takeda Pharmaceutical Co Ltd | Amgen Inc |
|---|---|---|---|---|---|
| Headquarters | Denmark | Germany | France | Japan | United States of America |
| City | Koebenhavn V | Leverkusen | Paris | Chuo-Ku | Thousand Oaks |
| State/Province | - | Nordrhein-Westfalen | Ile-de-France | Tokyo | California |
| No. of Employees | 2,204 | 99,723 | 87,994 | 49,095 | 26,700 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Deirdre P. Connelly | Chairman | Executive Board | 2017 | 62 |
| Jan G. J. Van de Winkel, Ph.D. | Chief Executive Officer; President | Senior Management | 2010 | 61 |
| Anthony Pagano | Chief Financial Officer; Executive Vice President | Senior Management | 2020 | 45 |
| Anthony Mancini | Executive Vice President; Chief Operating Officer | Senior Management | 2020 | 52 |
| Martine van Vugt | Executive Vice President; Chief Strategy Officer | Senior Management | 2023 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward